Accelerating Drug Development
-
Kalon Biotherapeutics, LLC
Kalon Biotherapeutics is a biologics development and manufacturing service provider in College Station, Texas. Kalon accelerates drug development with its state of the art drug discovery center and expert project management staff. Kalon’s pharmaceutical development centers provide a flexible and scalable platform capable of supporting all classes of drug development and biomanufacturing products.
-
National Center for Therapeutics Manufacturing
Kalon Biotherapeutics operates the National Center for Therapeutics Manufacturing (NCTM), offering flexible manufacturing environments and technologies to biological therapeutics. The center includes 110,000 square feet of cGMP space, and houses over 20 modular cleanrooms. The NCTM’s facilities are state-of-the-art and are ideal for biotherapeutics research, development, workforce training and GMP manufacturing.
-
Drug Development Project Management
Kalon Biotherapeutics utilizes a proven and active communicative approach to manage all aspects of Phase II and Phase III clinical manufacturing. Its project management systems allow for an open communication philosophy to accelerate the drug development process at every stage. Kalon’s experienced project management teams help to set project goals, objectives and deliverables to help achieve success in accelerating drug development.
-
Modular Cleanrooms
The National Center of Therapeutics Manufacturing’s portable cleanroom modular pods are walk-in biological safety cabinets with flexibility in size to accommodate upstream and downstream bioprocessing activities. Each modular cleanroom is used for a unique, biologically distinct technology to eliminate cross contamination and comply with all regulatory agency standards. These cleanroom labs offer the flexibility that a drug manufacturer needs to develop drugs at any location.
News
-
U.S. Sen. Ted Cruz Praises Work at Texas A&M System Biomedical Facilities
4/2/13 • READ ARTICLE -
GlaxoSmithKline Plans Texas Flu Plant to Respond to Pandemics
3/26/13 • READ ARTICLE -
Texas A&M System and GlaxoSmithKline Receive U.S. Government Approval to Establish Influenza Vaccine Fa
3/26/13 • READ ARTICLE